

**Author(s):** It includes GERD recommendation

**Question:** RYGB compared to sleeve gastrectomy for weight loss in obese patients

**Setting:** Question 6

**Bibliography:**

Certainty assessment							N <sub>o</sub> of patients		Effect		Certainty	Importance
N <sub>o</sub> of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	RYGB	sleeve gastrectomy	Relative (95% CI)	Absolute (95% CI)		
<b>EWL (follow up: range 1 years to 5 years; assessed with: %)</b>												
11	randomised trials	serious	not serious	not serious	not serious	none			-	MD 4 % higher (14 lower to 8.2 higher)	⊕⊕⊕○ MODERATE	CRITICAL
<b>T2DM (follow up: range 3 months to 5 years)</b>												
25	randomised trials	serious	not serious	not serious	not serious	none	117/226 (51.8%)	104/223 (46.6%)	RR 0.89 (0.74 to 1.06)	51 fewer per 1.000 (from 121 fewer to 28 more)	⊕⊕⊕○ MODERATE	IMPORTANT
<b>Long-term major complications (follow up: range 1 months to 5 years)</b>												
6	randomised trials	serious	serious	not serious	serious	none	6/345 (1.7%)	3/350 (0.9%)	OR 1.56 (0.51 to 4.76)	5 more per 1.000 (from 4 fewer to 31 more)	⊕○○○ VERY LOW	CRITICAL
<b>Long term minor complications (follow up: range 1 months to 5 years)</b>												
6	randomised trials	serious	serious	not serious	not serious	none	17/205 (8.3%)	10/213 (4.7%)	OR 1.56 (0.68 to 3.57)	24 more per 1.000 (from 15 fewer to 103 more)	⊕⊕○○ LOW	IMPORTANT
<b>Hypertension remission (follow up: range 2 months to 5 years)</b>												
21	observational studies	serious	serious	serious	not serious	none	552/920 (60.0%)	323/632 (51.1%)	OR 0.70 (0.86 to 0.87)	89 fewer per 1.000 (from 38 fewer to 35 fewer)	⊕○○○ VERY LOW	IMPORTANT
<b>Dyslipidemia resolution (follow up: range 2 months to 5 years)</b>												

14	observational studies	serious	serious	serious	not serious	none	489/689 (71.0%)	287/580 (49.5%)	<b>OR 0.42</b> (0.33 to 0.53)	<b>203 fewer per 1.000</b> (from 251 fewer to 153 fewer)	⊕○○○ VERY LOW	IMPORTANT
----	-----------------------	---------	---------	---------	-------------	------	--------------------	--------------------	----------------------------------	---	------------------	-----------

**GERD (follow up: range 2 months to 5 years)**

11	observational studies	serious	serious	serious	not serious	strong association	109/147 (74.1%)	26/93 (28.0%)	<b>OR 0.11</b> (0.06 to 0.21)	<b>239 fewer per 1.000</b> (from 257 fewer to 204 fewer)	⊕○○○ VERY LOW	IMPORTANT
----	-----------------------	---------	---------	---------	-------------	--------------------	--------------------	------------------	----------------------------------	---	------------------	-----------

**OSAS (follow up: range 2 months to 5 years)**

11	observational studies	serious	not serious	serious	not serious	none	205/270 (75.9%)	160/247 (64.8%)	<b>OR 0.44</b> (0.19 to 1.04)	<b>201 fewer per 1.000</b> (from 389 fewer to 9 more)	⊕○○○ VERY LOW	IMPORTANT
----	-----------------------	---------	-------------	---------	-------------	------	--------------------	--------------------	----------------------------------	--	------------------	-----------

**Minor operative morbidity (follow up: range 1 months to 5 years)**

6	randomised trials	serious <sup>a</sup>	serious <sup>b</sup>	not serious	not serious	none	28/316 (8.9%)	19/317 (6.0%)	<b>OR 1.43</b> (0.60 to 3.23)	<b>24 more per 1.000</b> (from 23 fewer to 111 more)	⊕⊕○○ LOW	IMPORTANT
---	-------------------	----------------------	----------------------	-------------	-------------	------	------------------	------------------	----------------------------------	---	-------------	-----------

**Major operative morbidity (follow up: range 1 months to 5 years)**

6	randomised trials	serious <sup>a</sup>	serious <sup>b</sup>	not serious	not serious	none	26/346 (7.5%)	12/347 (3.5%)	<b>OR 2.04</b> (1.00 to 4.16)	<b>34 more per 1.000</b> (from 0 fewer to 95 more)	⊕⊕○○ LOW	CRITICAL
---	-------------------	----------------------	----------------------	-------------	-------------	------	------------------	------------------	----------------------------------	---	-------------	----------

**GERD remission in pre-existing GERD (follow up: 5 years)**

1	randomised trials	serious	not serious	not serious	not serious	none	104	101	-	<b>AD 0.36 % lower</b> (0.57 lower to 0.15 lower)	⊕⊕⊕○ MODERATE	IMPORTANT
---	-------------------	---------	-------------	-------------	-------------	------	-----	-----	---	--	------------------	-----------

**De novo GERD (follow up: 5 years)**

1	randomised trials	serious	not serious	not serious	serious	none	56	57	-	AD <b>0.31</b> % <b>lower</b> (0.08 lower to 0.54 lower)	⊕⊕○○ LOW	IMPORTANT
---	-------------------	---------	-------------	-------------	---------	------	----	----	---	---	-------------	-----------

**CI:** Confidence interval; **MD:** Mean difference; **RR:** Risk ratio; **OR:** Odds ratio

**Explanations**

- a. Heterogeneity between the studies
- b. Inconsistency between the studies